Chemomab Therapeutics (CMMB) Shares Outstanding (Weighted Average) (2017 - 2025)

Chemomab Therapeutics (CMMB) has 9 years of Shares Outstanding (Weighted Average) data on file, last reported at $510.2 million in Q4 2025.

• For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 42.11% year-over-year to $510.2 million; the trailing twelve-month figure through Dec 2025 stood at $510.2 million (up 42.11% YoY), and the FY2025 full-year result was $510.2 million, up 42.11% from the prior year.
• Shares Outstanding (Weighted Average) for Q4 2025 stood at $510.2 million, up from $494.3 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $510.2 million in Q4 2025 and bottomed at $156.8 million in Q1 2021.
• The 5-year median for Shares Outstanding (Weighted Average) is $228.5 million (2022), against an average of $284.0 million.
• The widest annual swing landed in 2021, when Shares Outstanding (Weighted Average) soared 69.66%; it then dropped 3.11% in 2023.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $207.5 million in 2021, then climbed by 9.7% to $227.6 million in 2022, then rose by 3.26% to $235.0 million in 2023, then surged by 52.79% to $359.0 million in 2024, then soared by 42.11% to $510.2 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $510.2 million (Q4 2025), $494.3 million (Q3 2025), and $459.8 million (Q2 2025), per Business Quant data.

Peer Comparison